Regenxbio (RGNX) Tops Q3 EPS by $1.24, Revenues Beat

Regenxbio (NASDAQ: RGNX) reported Q3 EPS of $0.23, $1.24 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $98.91 million versus the consensus estimate of $21.37 million.

"We have made several important advancements in our clinical pipeline during the third quarter of 2020, with continued focus on execution during the COVID-19 pandemic. I'm pleased that two Phase II trials are underway for the treatment of wet AMD and diabetic retinopathy using the suprachoroidal approach for the delivery of RGX-314. In addition, we have expanded our RGX-121 program for patients with MPS II to gain additional insight into the potential treatment effects of this one-time gene therapy candidate in more patients, and we have dosed additional patients in the second cohort of the ongoing Phase I/II trial. I look forward to providing additional updates on all of our clinical programs in 2021, as we continue to focus on the significant unmet medical needs in both large indications and rare diseases," said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO.

"The overall progress of gene therapy treatments continues to be encouraging, as we see additional patients around the world treated with Zolgensma®, the first approved gene therapy based on REGENXBIO's NAV Technology Platform," continued Mr. Mills. "We maintain our focus on our important relationships with partners and licensees in the gene therapy space, with a strong focus on patient needs and innovative approaches to treat disease."

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Regenxbio Inc. (RGNX) PT Raised to $32 at Baird
• Waterdrop names Qianfei Chang as independent director
• Regenxbio Inc. (RGNX) PT Raised to $18 at Leerink